What is enoxaparin and why is it important to Amphastar's business?

Enoxaparin (brand name Lovenox, Clexane internationally) is a low molecular weight heparin (LMWH) — an injectable anticoagulant (blood thinner) used to prevent and treat blood clots (deep vein thrombosis, pulmonary embolism) in hospitalized patients and as a bridge anticoagulant for patients transitioning between oral anticoagulants. Enoxaparin's market characteristics: enoxaparin is an essential hospital medication; every major hospital uses enoxaparin for post-surgical DVT prophylaxis, treatment of blood clots in hospitalized patients, and anticoagulation in cardiac patients; the market is large (hundreds of millions of doses annually in the U.S.). Enoxaparin as a complex generic: enoxaparin is derived from porcine intestinal mucosa heparin through a complex fractionation process; the product's complexity (it's a mixture of polysaccharides, not a single chemical entity) made generic approval difficult; the FDA required complex comparability studies for generic enoxaparin approval; Amphastar received one of the first FDA approvals for generic enoxaparin in 2010 and has been a leading supplier since. Strategic importance to Amphastar: enoxaparin provides a high-volume, high-market-share product in Amphastar's hospital injectable distribution network; the established hospital relationships from enoxaparin facilitate placement of Amphastar's other injectable products (glucagon, epinephrine, naloxone); enoxaparin revenue is stable but subject to ongoing pricing pressure as more generic manufacturers have entered the market.

What is the premium IOL market and how large is it?

The U.S. performs approximately 4 million cataract surgeries annually — one of the most common surgical procedures. IOL categories: Standard monofocal IOL — covered by Medicare and most insurance; patients can see clearly at one distance (typically far) and need reading glasses for near vision; surgeons receive a standard professional fee and hospitals receive standard facility payments for monofocal cataract surgery. Premium IOLs (out-of-pocket upgrade, typically $1,500-3,000 per eye above insurance coverage): Toric IOLs — correct astigmatism (corneal irregularity causing blurred vision); patients with significant astigmatism who want crisp distance vision without glasses benefit from toric IOLs; Alcon AcrySof IQ Toric, J&J Tecnis Toric are leaders. Multifocal IOLs — provide vision at multiple distances simultaneously; reduce reading glasses need; trade-off is potential halos and glare; Alcon Panoptix, J&J Synergy are leaders. Extended Depth-of-Focus (EDOF) IOLs — provide a range of vision without the halos of multifocals; J&J Tecnis Symfony is a leading EDOF. Light Adjustable Lens (LAL) — RxSight's unique adjustable system. Premium IOL penetration: approximately 10-15% of cataract patients choose premium IOLs; as Baby Boomers have cataract surgery and increasingly pay for vision quality, premium IOL adoption is growing; premium IOL average selling prices to surgeons are $300-800 per lens (at cost; total patient premium is $1,500-3,000 per eye).

What are biosimilars and what biosimilar programs is Amphastar developing?

Biosimilars are FDA-approved biological drugs demonstrated to be highly similar to an already-approved reference biological product (the 'reference biologic' or 'originator') with no clinically meaningful differences in safety, purity, or potency. Biological drugs are large, complex molecules (proteins) made in living cells — unlike small-molecule chemical drugs that can be exactly replicated as generics, biologics are complex enough that 'biosimilar' (highly similar) rather than 'generic' is the regulatory standard. Biosimilar approval process: biosimilar applicants must demonstrate analytical similarity (the biosimilar's protein structure, function, and characteristics are highly similar to the reference product) and clinical comparability (safety and efficacy in clinical trials or based on pharmacokinetic/pharmacodynamic studies); the FDA's biosimilar pathway (351(k)) is more demanding than generic drug approval (505(b)(2) or ANDA). Amphastar's biosimilar programs: Insulin glargine biosimilar — reference product is Lantus (Sanofi), a long-acting insulin used by type 1 and 2 diabetics; Amphastar received FDA approval for insulin glargine injection in 2021 under the Semglee co-development arrangement; the insulin market is enormous ($25B+ in the U.S.) but competitive with multiple biosimilar entrants. Exenatide biosimilar — reference is Byetta (AstraZeneca/AZ), an injectable GLP-1 receptor agonist for type 2 diabetes. Biosimilar markets have been slower to develop in the U.S. than anticipated due to payer contracting complexities, but pricing pressure on biologics is an increasing regulatory and commercial focus.

brimindinvest.com / compare / rxst-vs-amphLIVE

RXST

RxSight, Inc. · Healthcare - Ophthalmic Medical Devices

$4.73

-20.50% this month

VERSUS

⟷

COMPARE

AMPH

Amphastar Pharmaceuticals, Inc. · Healthcare - Specialty Injectable Pharmaceuticals

$18.81

+5.56% this month

Scoreboard verdict

Across AI score, momentum, valuation, upside, operating margin

RXST

2

AMPH

2

MIXED SETUP

Comparison scoreboard

MIXED SETUP

AI Score

RXST 22.2

AMPH ✓32.7

1Y Return

RXST -65.90%

AMPH ✓-25.77%

Fwd P/E

RXST ✓-8.45

AMPH 5.99

Target Up.

RXST ✓+85.74%

AMPH +21.39%

Op. Margin

RXST N/A

AMPH N/A

Metrics last refreshed: 6/20/2026

Quick take

RXST vs AMPH Stock Comparison: AI Score, Valuation, Performance and Upside

RXST (RxSight) and AMPH (Amphastar Pharmaceuticals) are both niche healthcare companies with differentiated product strategies — RxSight has a unique adjustable IOL system enabling post-cataract-surgery vision fine-tuning that no competitor replicates, requiring LDD device network expansion for commercial scale, while Amphastar provides a diversified portfolio of difficult-to-manufacture specialty injectable and inhalation pharmaceuticals with vertically integrated manufacturing. RxSight is a high-growth premium medical device; Amphastar is a profitable specialty generic pharma.

RXST vs AMPH is unique adjustable IOL ophthalmic device with post-surgery vision customization capability (RxSight's Light Adjustable Lens providing ophthalmologists a differentiated premium IOL system with no direct competition, growing through LDD device network expansion and premium IOL adoption) versus diversified specialty injectable pharmaceutical manufacturer with vertically integrated production (Amphastar's portfolio of enoxaparin, glucagon, epinephrine, and naloxone providing stable hospital injectable revenue while developing biosimilars) — premium medical device growth versus specialty generic pharma stability.

Live analysis · updated 6/20/2026

RXST and AMPH are closely matched — they split the tracked metrics evenly. AMPH has delivered stronger 1-year price return (-25.77% vs -65.90%), though RXST trades at the lower forward P/E (-8.45x vs 5.99x). Analyst consensus implies meaningfully more upside for RXST (+85.74%) than for AMPH (+21.39%).

Normalized 1Y performance

RXST

AMPH

Recent returns

RXST

AMPH

Analyst price targets & sentiment

RXST · 7 analysts

Price target range

analyst low$7.50
analyst high$11.00
analyst mean$8.79
current price$4.73

+85.7% upside to analyst mean

AMPH · 6 analysts

Price target range

analyst low$19.00
analyst high$30.00
analyst mean$22.83
current price$18.81

+21.4% upside to analyst mean

Who should consider this stock?

RXST may suit investors who:

→Believe the Light Adjustable Lens's unique post-surgery vision optimization capability will drive sustained ophthalmologist adoption and premium pricing as cataract surgery patients increasingly seek optimal visual outcomes
→Value RxSight's proprietary, clinically differentiated technology with no direct competition as creating pricing power and defensible market position in the premium IOL segment
→Are comfortable with a medical device company that monetizes through a capital-equipment-plus-consumables model (LDD devices placed at practices + LAL lens sales per procedure)

AMPH may suit investors who:

→Want specialty pharmaceutical exposure with diversified injectable and inhalation product revenue providing more stability than single-product biotech companies
→Value Amphastar's vertically integrated manufacturing providing cost advantages and supply reliability in the injectable pharmaceutical market
→See Amphastar's biosimilar programs (insulin glargine) as providing upside potential beyond the core generic injectable business if biosimilar programs achieve approval and market penetration

Performance & AI score

Metric	RXST	AMPH
AI score	22.2	32.7
AI rank	#4255	#2052
Latest close	$4.73	$18.81
1M return	-20.50%	+5.56%
6M return	-62.46%	-27.85%
1Y return	-65.90%	-25.77%

$10,000 invested — hypothetical growth (dividends reinvested)

How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?

Period	RXST	AMPH
1Y ago	$3.41K (-65.9%) started 2025-06-18	$7.42K (-25.8%) started 2025-06-18
5Y ago	$2.96K (-70.4%) started 2021-07-30	$9.33K (-6.7%) started 2021-06-18
10Y ago	$2.96K (-70.4%) started 2021-07-30	$12.7K (+27.0%) started 2016-06-20

Hypothetical — past performance does not guarantee future results.

Valuation & upside potential

Metric	RXST	AMPH
Market cap	$195.81M	$829.39M
Trailing P/E	N/A	11.33
Forward P/E	-8.45	5.99
Price/Sales	1.54	1.15
EV/Revenue	-0.10	1.77
Analyst target	$8.79	$22.83
Target upside	+85.74%	+21.39%

Growth, profitability & risk

Metric	RXST	AMPH
Revenue growth	-18.50%	0.40%
Earnings growth	N/A	-72.50%
EPS growth	N/A	-72.50%
FCF margin	-0.76%	+14.31%
Operating margin	N/A	N/A
Profit margin	-36.59%	11.00%
ROIC proxy	-17.06%	10.39%
Return on equity	-17.06%	10.39%
Dividend yield	0.00%	0.00%
Beta	1.13	0.90
Debt/equity	4.05	88.75
Current ratio	10.20	3.85
Quick ratio	8.78	2.73

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

RXST max drawdown66.91%

AMPH max drawdown45.25%

RXST max wkly drop41.75%

AMPH max wkly drop29.09%

5Y risk snapshot

RXST max drawdown92.86%

AMPH max drawdown74.05%

RXST max wkly drop41.75%

AMPH max wkly drop29.09%

10Y risk snapshot

RXST max drawdown92.86%

AMPH max drawdown74.05%

RXST max wkly drop41.75%

AMPH max wkly drop29.09%

Performance metrics by period

Period	Metric	RXST	AMPH
1Y	Growth	-65.90%	-25.77%
	CAGR	-65.92%	-25.78%
	Sharpe ratio	-1.12	-0.36
	Max drawdown	66.91%	45.25%
	Max daily drop	37.84%	23.63%
	Max wkly drop	41.75%	29.09%
5Y	Growth	-70.44%	-6.74%
	CAGR	-22.08%	-1.39%
	Sharpe ratio	-0.07	0.10
	Max drawdown	92.86%	74.05%
	Max daily drop	37.94%	23.63%
	Max wkly drop	41.75%	29.09%
10Y	Growth	-70.44%	+27.01%
	CAGR	-22.08%	+2.42%
	Sharpe ratio	-0.07	0.17
	Max drawdown	92.86%	74.05%
	Max daily drop	37.94%	24.70%
	Max wkly drop	41.75%	29.09%

Business comparison

Category	RXST	AMPH
Company	RxSight, Inc.	Amphastar Pharmaceuticals, Inc.
Sector	Healthcare - Ophthalmic Medical Devices	Healthcare - Specialty Injectable Pharmaceuticals
Industry	N/A	N/A
Core business	RxSight is a commercial-stage ophthalmic medical device company commercializing the Light Adjustable Lens (LAL) system for cataract surgery. The LAL is a unique intraocular lens (IOL) that can be non-invasively adjusted after surgical implantation — the surgeon implants the LAL during routine cataract surgery, and then in the weeks following surgery, the lens's prescription (power and astigmatic correction) is fine-tuned using UV light treatment delivered by RxSight's Light Delivery Device (LDD). This allows the ophthalmologist to optimize the patient's vision based on actual post-surgery healing, achieving more precise vision correction than fixed-prescription IOLs that must be calculated before surgery.	Amphastar Pharmaceuticals is a specialty pharmaceutical company focused on difficult-to-manufacture injectable and inhalation products, including generic and branded specialty pharmaceuticals. Amphastar's product portfolio includes: enoxaparin (low molecular weight heparin — blood thinner), glucagon (hypoglycemia emergency treatment), epinephrine products (anaphylaxis treatment — EpiPen generics), naloxone (opioid overdose reversal), inhalation products (albuterol, budesonide, ipratropium), and pharmacy-compounding APIs. Amphastar also has biosimilar development programs (insulin glargine, exenatide biosimilar). Amphastar owns manufacturing facilities in California and China, providing vertically integrated production of injectable drug products.
Investor focus	Investors track RxSight's LAL system installations (number of LDD devices placed at ophthalmology practices), LAL unit volume growth (lenses implanted per LDD unit per year — utilization rate), revenue and gross margin trajectory, and the expansion of the LAL practice into new surgeon adopters.	Investors track Amphastar's product revenue mix and gross margin evolution (shift from lower-margin generic injectables toward higher-margin products), new product launch revenue contribution, biosimilar program progress, and operating leverage as higher-margin products scale.

RXST strengths

→First and only adjustable IOL system offering post-surgery vision optimization — the LAL's post-implantation adjustability is a genuinely unique technology in ophthalmic surgery; no competitor offers a comparable post-surgery vision customization capability
→Premium IOL category is growing as more patients opt for enhanced vision correction in cataract surgery — the premium IOL market (multifocal, toric, extended-depth-of-focus lenses) has grown as patients increasingly pay out-of-pocket for better vision outcomes beyond the standard monofocal lens covered by insurance
→Clinical data shows superior vision outcomes versus traditional IOLs — clinical trials demonstrated LAL patients achieving better uncorrected distance vision versus monofocal IOLs; high patient satisfaction and the precision of adjustable correction is clinically compelling

AMPH strengths

→Vertically integrated manufacturing provides cost advantages in injectable pharmaceuticals — Amphastar manufactures APIs (active pharmaceutical ingredients) and formulates finished products internally, reducing dependency on external API suppliers and providing cost control in a market where supply chain reliability is critical
→Difficult-to-manufacture product portfolio with regulatory complexity barriers — injectable and inhalation drug manufacturing requires substantial FDA regulatory compliance investment; the technical difficulty of injectable drug manufacturing creates higher barriers to entry than oral solid dosage forms
→Enoxaparin market position and diversified injectable portfolio — Amphastar is the leading generic enoxaparin supplier in the U.S.; low-molecular-weight heparins are essential medications in hospital settings; Amphastar's hospital-direct distribution model provides a stable institutional sales channel for its broader injectable portfolio

Risks to watch — RXST

→Capital-intensive LDD placement limits rapid growth — installing LDD devices at practices requires capital investment and training; surgeons must be credentialed for LAL procedures; the LDD placement network grows incrementally rather than explosively
→Premium IOL pricing requires patient out-of-pocket payment — LAL is a premium upgrade above standard insurance-covered cataract surgery; patient willingness to pay $2,000-4,000+ above insurance coverage for premium IOLs is the key demand driver; economic sensitivity affects premium IOL demand
→Competitive premium IOL alternatives from Alcon, J&J Vision — while LAL is unique, premium IOL alternatives (multifocal Panoptix, extended-depth TECNIS Symfony, toric lenses) compete for the premium IOL upgrade budget; ophthalmologists may continue using familiar premium alternatives

Risks to watch — AMPH

→Generic injectable pricing pressure is structural — generic injectable markets are competitive; pricing erosion as competitors enter markets for established generics (like enoxaparin) reduces revenue over time for any given product; Amphastar must continuously launch new products to offset commodity pricing on older generics
→Biosimilar development is expensive and uncertain — Amphastar's biosimilar programs (insulin glargine) require significant investment and face approval uncertainty; biosimilar markets once launched can be competitive with multiple approved biosimilars
→China manufacturing concentration creates geopolitical supply chain risk — Amphastar's Chinese manufacturing operations provide cost efficiency but create supply chain risk from U.S.-China trade tensions, quality incidents, or regulatory actions at the China facility

Frequently asked questions

Cataract surgery involves removing the eye's clouded natural lens and replacing it with an artificial intraocular lens (IOL). The challenge of traditional IOLs: before surgery, the surgeon measures the patient's eye (axial length, corneal curvature) and calculates the IOL power needed; however, exact outcomes are difficult to predict — the healing process, small measurement errors, and biological variability mean many patients still need glasses for optimal vision after cataract surgery with traditional IOLs; if the outcome is suboptimal, corrective procedures (laser vision correction) are required. The Light Adjustable Lens system: RxSight's LAL is made of a special photosensitive polymer; after surgical implantation, the patient's vision is allowed to stabilize over 2-4 weeks; the ophthalmologist then measures the patient's actual vision and uses RxSight's Light Delivery Device (LDD) to apply UV light to specific zones of the lens; the UV light polymerizes the photosensitive polymer, changing the lens curvature and adjusting the prescription; multiple adjustment sessions can be performed; when the patient is satisfied with their vision, a UV 'lock-in' treatment permanently fixes the lens prescription. Results: clinical trials showed approximately 75% of LAL patients achieved 20/20 or better uncorrected vision versus approximately 48% for standard monofocal IOLs; the adjustability allows correction of residual astigmatism and spherical error that would otherwise require glasses.

AI Prediction SignalNext 5 trading days

Members only

RXST

+2.8%BUY

AMPH

+1.1%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides